Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women

Arash Rafii Tabrizi, Sean D. McGrath, Morey A. Blinder, Timothy G. Buchman, Barbara A. Zehnbauer, Bradley D. Freeman

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Diagnosis of von Willebrand disease (vWD) is based on a panel of laboratory tests that measure the amount and function of von Willebrand factor (vWF). In population studies, vWF is higher in African Americans than Caucasians. Bleeding time, factor VIII activity (FVIII), vWF antigen (vWF:Ag), "vWF activity" ELISA (vWF:Act), ristocetin cofactor (vWF:RCof), and ristocetin-induced platelet aggregation (RIPA) were measured on 123 women with menorrhagia and 123 randomly selected control women; 70 cases and 76 controls were African American. Among controls, African Americans had significantly higher levels of vWF:Ag (mean 120 vs. 102 U/dl, P = 0.017). Among all subjects, African Americans had higher levels of vWF:Ag (mean 123 vs. 103, P = 0.001), vWF:Act (mean 101 vs. 89, P = 0.006), and FVIII (mean 118 vs. 104, P = 0.008). VWF:RCof did not differ between races (93 vs. 94 U/dl). RIPA was reduced in African Americans (P < 0.0001). In both races, women with type O blood differed significantly from those with other ABO types in vWF:Ag, vWF:Act, FVIII, and vWF:RCof. Based on criteria of two or more tests below race- and ABO-specific reference ranges, 6.5% of menorrhagia cases and 0.8% of controls were classified as having vWD, or its phenocopy. Among Caucasians, no controls and 7 cases (15.6%) were classified as affected, and in African Americans, 1 control (1.3%) and 1 case (1.4%) were so classified. Racial differences in vWF further complicate the issues surrounding diagnosis of vWD. The finding of increased vWF:Ag not accompanied by increased vWF:RCof has implications for understanding the structure-function relationships of vWF. Published 2001 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)125-129
Number of pages5
JournalAmerican Journal of Hematology
Volume67
Issue number2
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

von Willebrand Diseases
von Willebrand Factor
African Americans
Population
Ristocetin
Menorrhagia
Platelet Aggregation
Bleeding Time
Factor VIII

Keywords

  • ABO blood type
  • Factor VIII
  • Menorrhagia
  • Race
  • Von Willebrand disease

ASJC Scopus subject areas

  • Hematology

Cite this

Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women. / Tabrizi, Arash Rafii; McGrath, Sean D.; Blinder, Morey A.; Buchman, Timothy G.; Zehnbauer, Barbara A.; Freeman, Bradley D.

In: American Journal of Hematology, Vol. 67, No. 2, 2001, p. 125-129.

Research output: Contribution to journalArticle

Tabrizi, Arash Rafii ; McGrath, Sean D. ; Blinder, Morey A. ; Buchman, Timothy G. ; Zehnbauer, Barbara A. ; Freeman, Bradley D. / Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women. In: American Journal of Hematology. 2001 ; Vol. 67, No. 2. pp. 125-129.
@article{63a2076befb74cdd8b5decae6ae6ad4b,
title = "Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women",
abstract = "Diagnosis of von Willebrand disease (vWD) is based on a panel of laboratory tests that measure the amount and function of von Willebrand factor (vWF). In population studies, vWF is higher in African Americans than Caucasians. Bleeding time, factor VIII activity (FVIII), vWF antigen (vWF:Ag), {"}vWF activity{"} ELISA (vWF:Act), ristocetin cofactor (vWF:RCof), and ristocetin-induced platelet aggregation (RIPA) were measured on 123 women with menorrhagia and 123 randomly selected control women; 70 cases and 76 controls were African American. Among controls, African Americans had significantly higher levels of vWF:Ag (mean 120 vs. 102 U/dl, P = 0.017). Among all subjects, African Americans had higher levels of vWF:Ag (mean 123 vs. 103, P = 0.001), vWF:Act (mean 101 vs. 89, P = 0.006), and FVIII (mean 118 vs. 104, P = 0.008). VWF:RCof did not differ between races (93 vs. 94 U/dl). RIPA was reduced in African Americans (P < 0.0001). In both races, women with type O blood differed significantly from those with other ABO types in vWF:Ag, vWF:Act, FVIII, and vWF:RCof. Based on criteria of two or more tests below race- and ABO-specific reference ranges, 6.5{\%} of menorrhagia cases and 0.8{\%} of controls were classified as having vWD, or its phenocopy. Among Caucasians, no controls and 7 cases (15.6{\%}) were classified as affected, and in African Americans, 1 control (1.3{\%}) and 1 case (1.4{\%}) were so classified. Racial differences in vWF further complicate the issues surrounding diagnosis of vWD. The finding of increased vWF:Ag not accompanied by increased vWF:RCof has implications for understanding the structure-function relationships of vWF. Published 2001 Wiley-Liss, Inc.",
keywords = "ABO blood type, Factor VIII, Menorrhagia, Race, Von Willebrand disease",
author = "Tabrizi, {Arash Rafii} and McGrath, {Sean D.} and Blinder, {Morey A.} and Buchman, {Timothy G.} and Zehnbauer, {Barbara A.} and Freeman, {Bradley D.}",
year = "2001",
doi = "10.1002/ajh.1090",
language = "English",
volume = "67",
pages = "125--129",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women

AU - Tabrizi, Arash Rafii

AU - McGrath, Sean D.

AU - Blinder, Morey A.

AU - Buchman, Timothy G.

AU - Zehnbauer, Barbara A.

AU - Freeman, Bradley D.

PY - 2001

Y1 - 2001

N2 - Diagnosis of von Willebrand disease (vWD) is based on a panel of laboratory tests that measure the amount and function of von Willebrand factor (vWF). In population studies, vWF is higher in African Americans than Caucasians. Bleeding time, factor VIII activity (FVIII), vWF antigen (vWF:Ag), "vWF activity" ELISA (vWF:Act), ristocetin cofactor (vWF:RCof), and ristocetin-induced platelet aggregation (RIPA) were measured on 123 women with menorrhagia and 123 randomly selected control women; 70 cases and 76 controls were African American. Among controls, African Americans had significantly higher levels of vWF:Ag (mean 120 vs. 102 U/dl, P = 0.017). Among all subjects, African Americans had higher levels of vWF:Ag (mean 123 vs. 103, P = 0.001), vWF:Act (mean 101 vs. 89, P = 0.006), and FVIII (mean 118 vs. 104, P = 0.008). VWF:RCof did not differ between races (93 vs. 94 U/dl). RIPA was reduced in African Americans (P < 0.0001). In both races, women with type O blood differed significantly from those with other ABO types in vWF:Ag, vWF:Act, FVIII, and vWF:RCof. Based on criteria of two or more tests below race- and ABO-specific reference ranges, 6.5% of menorrhagia cases and 0.8% of controls were classified as having vWD, or its phenocopy. Among Caucasians, no controls and 7 cases (15.6%) were classified as affected, and in African Americans, 1 control (1.3%) and 1 case (1.4%) were so classified. Racial differences in vWF further complicate the issues surrounding diagnosis of vWD. The finding of increased vWF:Ag not accompanied by increased vWF:RCof has implications for understanding the structure-function relationships of vWF. Published 2001 Wiley-Liss, Inc.

AB - Diagnosis of von Willebrand disease (vWD) is based on a panel of laboratory tests that measure the amount and function of von Willebrand factor (vWF). In population studies, vWF is higher in African Americans than Caucasians. Bleeding time, factor VIII activity (FVIII), vWF antigen (vWF:Ag), "vWF activity" ELISA (vWF:Act), ristocetin cofactor (vWF:RCof), and ristocetin-induced platelet aggregation (RIPA) were measured on 123 women with menorrhagia and 123 randomly selected control women; 70 cases and 76 controls were African American. Among controls, African Americans had significantly higher levels of vWF:Ag (mean 120 vs. 102 U/dl, P = 0.017). Among all subjects, African Americans had higher levels of vWF:Ag (mean 123 vs. 103, P = 0.001), vWF:Act (mean 101 vs. 89, P = 0.006), and FVIII (mean 118 vs. 104, P = 0.008). VWF:RCof did not differ between races (93 vs. 94 U/dl). RIPA was reduced in African Americans (P < 0.0001). In both races, women with type O blood differed significantly from those with other ABO types in vWF:Ag, vWF:Act, FVIII, and vWF:RCof. Based on criteria of two or more tests below race- and ABO-specific reference ranges, 6.5% of menorrhagia cases and 0.8% of controls were classified as having vWD, or its phenocopy. Among Caucasians, no controls and 7 cases (15.6%) were classified as affected, and in African Americans, 1 control (1.3%) and 1 case (1.4%) were so classified. Racial differences in vWF further complicate the issues surrounding diagnosis of vWD. The finding of increased vWF:Ag not accompanied by increased vWF:RCof has implications for understanding the structure-function relationships of vWF. Published 2001 Wiley-Liss, Inc.

KW - ABO blood type

KW - Factor VIII

KW - Menorrhagia

KW - Race

KW - Von Willebrand disease

UR - http://www.scopus.com/inward/record.url?scp=0035003395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035003395&partnerID=8YFLogxK

U2 - 10.1002/ajh.1090

DO - 10.1002/ajh.1090

M3 - Article

VL - 67

SP - 125

EP - 129

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -